Premium
rhGGF2 protects against cisplatin‐induced neuropathy in the rat
Author(s) -
ter Laak Mariël P.,
Hamers Frank P.T.,
Kirk Cassandra J.,
Gispen Willem Hendrik
Publication year - 2000
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/(sici)1097-4547(20000415)60:2<237::aid-jnr13>3.0.co;2-5
Subject(s) - cisplatin , peripheral neuropathy , medicine , placebo , in vivo , nerve conduction velocity , saline , pharmacology , anesthesia , chemotherapy , neuroprotection , endocrinology , pathology , biology , diabetes mellitus , alternative medicine , microbiology and biotechnology
In many patients treated with cisplatin a peripheral sensory neuropathy develops. This side‐effect is considered dose‐limiting, and therefore restricts the total dose of cisplatin that can be administered. Recent in vitro and in vivo studies suggest that recombinant human Glial Growth Factor 2 (rhGGF2) has neuroprotective effects. This prompted us to investigate in a rat model whether rhGGF2 ameliorates cisplatin neuropathy. A total of 48 rats were randomly divided into four groups of 12 rats each. Three groups received cisplatin and were treated with either 0.1 mg/kg rhGGF2, 0.3 mg/kg rhGGF2 or placebo. The fourth group (saline/placebo) served as age‐matched controls. In the cisplatin/placebo treated rats a neuropathy developed, as determined by measurements of the nerve conduction velocity (NCV). Treatment with rhGGF2 dose‐dependently protected against the neuropathy. Histological examination and morphometric analysis revealed that rhGGF2 also protects against cisplatin‐induced changes in the morphology and size of DRG satellite cell nuclei. In a control study rhGGF2 did not affect normal NCV development. We conclude that rhGGF2 treatment is of benefit in the treatment of cisplatin neuropathy in the rat. J. Neurosci. Res. 60:237–244, 2000 © 2000 Wiley‐Liss, Inc.